Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology.
The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies.
Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | 0.00 Increased by +100.00% | -0.51 Increased by +100.00% |
| Mar 1, 24 | -0.72 Decreased by -28.57% | -0.51 Decreased by -41.18% |
| Nov 3, 23 | -0.55 Increased by +24.66% | -0.46 Decreased by -19.57% |
| Aug 7, 23 | -0.47 Decreased by -46.87% | -0.42 Decreased by -11.90% |
| May 11, 23 | -0.44 Decreased by -83.33% | -0.41 Decreased by -7.32% |
| Mar 9, 23 | -0.56 | -0.65 Increased by +13.85% |
| Nov 14, 22 | -0.73 | - |
| May 6, 22 | -0.32 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by -100.00% | -65.64 M Decreased by -67.10% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -50.71 M Decreased by -72.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -42.38 M Decreased by -44.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -39.40 M Decreased by -65.26% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 5.21 M Increased by +N/A% | -39.28 M Increased by +37.56% | Decreased by -753.99% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -29.35 M Decreased by -78.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -29.35 M Decreased by N/A% | Decreased by N/A% - |
| Mar 31, 22 | 0.00 Decreased by N/A% | -23.84 M Decreased by -842.67% | Decreased by N/A% - |